Bal Pharma News

Bal Pharma Q3FY26 Net Profit Surges 181.84% YoY

Bal Pharma Limited reported strong Q3FY26 results with net profit jumping 181.84% YoY to ₹194.62 lakhs. Revenue from operations grew 20.03% to ₹8,749.48 lakhs, driven by improved operational efficiency.

Bal Pharma Limited Reports Quarterly Results and Appoints New Independent Director

Bal Pharma Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company reported standalone revenue from operations of Rs 7,470.00 lakhs for the quarter, with a net profit of Rs 80.18 lakhs. For the half year, revenue stood at Rs 13,908.84 lakhs with net profit of Rs 175.68 lakhs. The Board also appointed Dr. Bheekamchand Mukesh as an additional Non-executive Independent Director. Dr. Mukesh brings 35 years of experience in pharmaceutical research, development and commercialization. The statutory auditors issued an unmodified opinion on the financial results.

Bal Pharma Sets September 18, 2025 as Record Date for Dividend Payment

Bal Pharma Limited's Board of Directors has fixed September 18, 2025 as the record date for dividend payment for the financial year ended March 31, 2025. The dividend payment is subject to shareholder approval at the company's 38th Annual General Meeting scheduled for September 25, 2025. The board decision was made at their meeting held on August 11, 2025.